Arbor Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Arbor Biotechnologies's estimated annual revenue is currently $21.5M per year.
- Arbor Biotechnologies's estimated revenue per employee is $155,000
- Arbor Biotechnologies's total funding is $304M.
Employee Data
- Arbor Biotechnologies has 139 Employees.
- Arbor Biotechnologies grew their employee count by -29% last year.
Arbor Biotechnologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Co-Founder, Head Translational Strategy | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Co-founder | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | VP, Head CNS | Reveal Email/Phone |
7 | SVP, Head Business Development | Reveal Email/Phone |
8 | Head Computational Biology and Data Science | Reveal Email/Phone |
9 | SVP | Reveal Email/Phone |
10 | Director Clinical Operations | Reveal Email/Phone |
Arbor Biotechnologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Arbor Biotechnologies?
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.
keywords:N/A
$304M
Total Funding
139
Number of Employees
$21.5M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arbor Biotechnologies News
TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...
Arbor Biotechnologies has raised a $215 million Series B co-led by Ally Bridge Group, TCG Crossover and Temasek. Based in the Boston area and founded in 2016, the life sciences company is developing precision gene-editing therapeutics to treat liver and CNS disease. Select Additional Investors ...
The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company ...
The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology compan ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.6M | 139 | 14% | $78.7M |
#2 | $19.5M | 139 | -21% | $110.8M |
#3 | $10.5M | 139 | 23% | $202M |
#4 | $7.5M | 139 | 58% | N/A |
#5 | $29.2M | 139 | 7% | N/A |